BTIG Research Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by BTIG Research in a research report issued on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock.

A number of other equities analysts have also recently weighed in on NRXP. Ascendiant Capital Markets raised their price objective on NRx Pharmaceuticals from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday, October 16th. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Finally, D. Boral Capital restated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $36.50.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP opened at $2.44 on Wednesday. The stock has a market capitalization of $68.56 million, a PE ratio of -1.04 and a beta of 1.91. NRx Pharmaceuticals has a 1 year low of $1.15 and a 1 year high of $6.01. The company’s 50 day simple moving average is $2.83 and its two-hundred day simple moving average is $2.89.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $6.83 million. On average, research analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Anson Funds Management LP lifted its stake in NRx Pharmaceuticals by 26.2% during the 3rd quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock valued at $6,683,000 after acquiring an additional 420,129 shares during the period. Two Sigma Investments LP boosted its stake in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after acquiring an additional 82,781 shares during the period. AdvisorShares Investments LLC increased its position in NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after acquiring an additional 78,339 shares during the last quarter. Finally, One Wealth Management Investment & Advisory Services LLC boosted its position in NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares during the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.